Drug Search Results

Omidenepag

Alternative Names: omidenepag, de-117, de117, de 117, omlonti
Latest Update: 2024-08-19
Latest Update Note: News Article

Product Description

Mechanisms of Action: EP2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Approved

Approved Indications: Hypertension | Glaucoma | Glaucoma, Open-Angle

Company: Santen
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Omidenepag

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Glaucoma, Open-Angle|Hypertension

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
011711IN	P3	Completed	Glaucoma, Open-Angle\|Hypertension	2022-01-13

Recent News Events

Date	Type	Title
08/19/2024	News Article	Visiox Pharmaceuticals, Inc. Announces Transformative Merger with Ocuvex Therpeutics, Inc.
01/29/2024	News Article	PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form S-4 to the SEC in Connection with the Previously Announced Proposed Business Combination
12/27/2023	News Article	Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
08/17/2023	News Article	Visiox Pharma Appoints Richard J. Rubino to Board of Directors

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions